The Anaplastic Oligoastrocytoma drugs in development market research report provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Anaplastic Oligoastrocytoma. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Anaplastic Oligoastrocytoma by nine companies/universities/institutes. The top development phase for Anaplastic Oligoastrocytoma is phase i with four drugs in that stage. The Anaplastic Oligoastrocytoma pipeline has seven drugs in development by companies and two by universities/ institutes. Some of the companies in the Anaplastic Oligoastrocytoma pipeline products market are: Boehringer Ingelheim International, TheraBiologics and Wurzburg University Hospital.

The key targets in the Anaplastic Oligoastrocytoma pipeline products market include Transforming Growth Factor Beta (TGFb) , Vascular Endothelial Growth Factor Receptor 3 (Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 or VEGFR3 or FLT4 or EC, and Vimentin (Epididymis Luminal Protein 113 or VIM).

The key mechanisms of action in the Anaplastic Oligoastrocytoma pipeline product include Transforming Growth Factor Beta (TGFB) Inhibitor with one drug in Preclinical. The Anaplastic Oligoastrocytoma pipeline products include seven routes of administration with the top ROA being Oral and four key molecule types in the Anaplastic Oligoastrocytoma pipeline products market including Small Molecule, and Oncolytic Virus.

Anaplastic Oligoastrocytoma overview

Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass. These brain cells are known as glial cells, which normally protect and support nerve cells in the brain. Symptoms include seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy and surgery.

For a complete picture of Anaplastic Oligoastrocytoma’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.